168 related articles for article (PubMed ID: 16722831)
1. Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome.
Paragh G; Seres I; Harangi M; Erdei A; Audikovszky M; Debreczeni L; Kovácsay A; Illyés L; Pados G
Br J Clin Pharmacol; 2006 Jun; 61(6):694-701. PubMed ID: 16722831
[TBL] [Abstract][Full Text] [Related]
2. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
Rizos E; Bairaktari E; Ganotakis E; Tsimihodimos V; Mikhailidis DP; Elisaf M
J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):219-26. PubMed ID: 12490967
[TBL] [Abstract][Full Text] [Related]
3. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
Balogh Z; Seres I; Harangi M; Kovács P; Kakuk G; Paragh G
Diabetes Metab; 2001 Nov; 27(5 Pt 1):604-10. PubMed ID: 11694861
[TBL] [Abstract][Full Text] [Related]
4. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
[TBL] [Abstract][Full Text] [Related]
5. Paraoxonase-1 (PON1) activity in patients with coronary artery diseases and in diabetic patients.
Amine K; Atouk A; Moussamih S; Saile R; Mikou A; Kettani A
Ann Biol Clin (Paris); 2011; 69(6):671-7. PubMed ID: 22123566
[TBL] [Abstract][Full Text] [Related]
6. Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis.
Asefi M; Vaisi-Raygani A; Bahrehmand F; Kiani A; Rahimi Z; Nomani H; Ebrahimi A; Tavilani H; Pourmotabbed T
Br J Dermatol; 2012 Dec; 167(6):1279-86. PubMed ID: 22835076
[TBL] [Abstract][Full Text] [Related]
7. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome.
Mackness B; Quarck R; Verreth W; Mackness M; Holvoet P
Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1545-50. PubMed ID: 16627808
[TBL] [Abstract][Full Text] [Related]
8. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z
Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515
[TBL] [Abstract][Full Text] [Related]
9. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
Sardo MA; Campo S; Bonaiuto M; Bonaiuto A; Saitta C; Trimarchi G; Castaldo M; Bitto A; Cinquegrani M; Saitta A
Curr Med Res Opin; 2005 May; 21(5):777-84. PubMed ID: 15969877
[TBL] [Abstract][Full Text] [Related]
10. Persistent elevation of paraoxonase-1 specific enzyme activity after weight reduction in obese non-diabetic men with metabolic syndrome.
Liang KW; Lee WJ; Lee IT; Lee WL; Lin SY; Hsu SL; Wan CJ; Yu CY; Tsai IC; Fu CP; Ting CT; Sheu WH
Clin Chim Acta; 2011 Sep; 412(19-20):1835-41. PubMed ID: 21704607
[TBL] [Abstract][Full Text] [Related]
11. Elevated HDL2-paraoxonase and reduced CETP activity are associated with a dramatically lower ratio of LDL-cholesterol/total cholesterol in a hypercholesterolemic and hypertriglyceridemic patient.
Lee JH; Park JH; Lee SH; Kim JR; Cho KH
Int J Mol Med; 2010 Jun; 25(6):945-51. PubMed ID: 20428800
[TBL] [Abstract][Full Text] [Related]
12. Oxidation resistance of LDL in hypertriglyceridaemic patients treated with ciprofibrate.
Nagyová A; Raslová K; Ginter E
Physiol Res; 1998; 47(3):185-90. PubMed ID: 9803483
[TBL] [Abstract][Full Text] [Related]
13. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
[TBL] [Abstract][Full Text] [Related]
14. Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage.
Raslová K; Dobiásová M; Nagyová A; Fábry R; Rauchová H; Dusinská M
Eur J Clin Pharmacol; 1998; 54(9-10):697-9. PubMed ID: 9923570
[TBL] [Abstract][Full Text] [Related]
15. Hypochlorous acid and low serum paraoxonase activity in haemodialysis patients: an in vitro study.
Sutherland WH; de Jong SA; Walker RJ
Nephrol Dial Transplant; 2004 Jan; 19(1):75-82. PubMed ID: 14671042
[TBL] [Abstract][Full Text] [Related]
16. Oxidized to non-oxidized lipoprotein ratios are associated with arteriosclerosis and the metabolic syndrome in diabetic patients.
Girona J; Manzanares JM; Marimón F; Cabré A; Heras M; Guardiola M; Ribalta J; Masana L
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):380-7. PubMed ID: 17904830
[TBL] [Abstract][Full Text] [Related]
17. High-density lipoprotein composition and paraoxonase activity in Type I diabetes.
Valabhji J; McColl AJ; Schachter M; Dhanjil S; Richmond W; Elkeles RS
Clin Sci (Lond); 2001 Dec; 101(6):659-70. PubMed ID: 11724654
[TBL] [Abstract][Full Text] [Related]
18. PON1 activity is inversely related to LDL apoB carbonyl content in patients with coronary artery disease.
Sharma R; Singh B; Mahajan M
Kaohsiung J Med Sci; 2007 May; 23(5):225-31. PubMed ID: 17525004
[TBL] [Abstract][Full Text] [Related]
19. Impaired paraoxonase-1 status in obese children. Relationships with insulin resistance and metabolic syndrome.
Ferré N; Feliu A; García-Heredia A; Marsillach J; París N; Zaragoza-Jordana M; Mackness B; Mackness M; Escribano J; Closa-Monasterolo R; Joven J; Camps J
Clin Biochem; 2013 Dec; 46(18):1830-6. PubMed ID: 24028901
[TBL] [Abstract][Full Text] [Related]
20. Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate.
Turay J; Grniaková V; Valka J
Drugs Exp Clin Res; 2000; 26(3):83-8. PubMed ID: 10941600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
